These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31009516)

  • 1. Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
    Noyan S; Gurdal H; Gur Dedeoglu B
    PLoS One; 2019; 14(4):e0215894. PubMed ID: 31009516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer.
    Zhang M; Li Z; Liu X
    Asian Pac J Cancer Prev; 2021 Nov; 22(11):3693-3703. PubMed ID: 34837929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
    Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
    DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
    Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
    Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
    Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
    Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
    Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
    J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma.
    Li J; Liu X; Li C; Wang W
    J Cell Biochem; 2019 Aug; 120(8):12412-12421. PubMed ID: 30825222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway.
    Kwon YS; Nam KS; Kim S
    Biochem Pharmacol; 2021 Aug; 190():114635. PubMed ID: 34058187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.
    Liu X; Li G
    Int J Clin Exp Pathol; 2015; 8(9):10605-14. PubMed ID: 26617770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells.
    Fu R; Tong JS
    J Cell Mol Med; 2020 Jul; 24(13):7600-7608. PubMed ID: 32410348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
    Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
    Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
    Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function of RasGRP3 in the formation and progression of human breast cancer.
    Nagy Z; Kovács I; Török M; Tóth D; Vereb G; Buzás K; Juhász I; Blumberg PM; Bíró T; Czifra G
    Mol Cancer; 2014 Apr; 13():96. PubMed ID: 24779681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-18a-5p attenuates HER2-positive breast cancer development by regulating PI3K/AKT pathway.
    Liu Y; Yang H
    Cancer Biol Ther; 2023 Dec; 24(1):2224512. PubMed ID: 37394766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
    Berns K; Sonnenblick A; Gennissen A; Brohée S; Hijmans EM; Evers B; Fumagalli D; Desmedt C; Loibl S; Denkert C; Neven P; Guo W; Zhang F; Knijnenburg TA; Bosse T; van der Heijden MS; Hindriksen S; Nijkamp W; Wessels LF; Joensuu H; Mills GB; Beijersbergen RL; Sotiriou C; Bernards R
    Clin Cancer Res; 2016 Nov; 22(21):5238-5248. PubMed ID: 27172896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-204 inhibits the proliferation and metastasis of breast cancer cells by targeting PI3K/AKT pathway.
    Fan X; Fang X; Liu G; Xiong Q; Li Z; Zhou W
    J BUON; 2019; 24(3):1054-1059. PubMed ID: 31424660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anesthetic propofol epigenetically regulates breast cancer trastuzumab resistance through IL-6/miR-149-5p axis.
    Tian D; Tian M; Ma ZM; Zhang LL; Cui YF; Li JL
    Sci Rep; 2020 Jun; 10(1):8858. PubMed ID: 32483313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.